Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

ICER 2020 Priorities Include Drugs For Ulcerative Colitis, NASH And Gene Therapies

Jul 10 2019

• By Jessica Merrill

Arrows miss target

Related Content

Bluebird Pushes For Zynteglo Pricing Of Five €315K Annual Installments

Jun 14 2019

CymaBay Alters NASH Hypothesis After Phase IIb Failure In Hepatic Fat Reduction

Jun 11 2019

BioMarin Says It's Got The Hemophilia Therapy Data For Approval And Value

May 28 2019

It's Official: Novartis SMA Gene Therapy Zolgensma Is World's Most Expensive Drug

May 24 2019

NASH Pipeline: Racing To The Finish

Mar 21 2019

Takeda's Entyvio Beats Humira In Head-To-Head Ulcerative Colitis Trial

Mar 13 2019

Related Companies

Biohaven Pharmaceutical Holding Company Ltd.

Allergan plc

Eli Lilly and Company

Johnson & Johnson

Takeda Pharmaceutical Co. Ltd.

AbbVie Inc.

Intercept Pharmaceuticals, Inc.

CymaBay Therapeutics, Inc.

Genfit SA

Genetix Biotherapeutics

BioMarin Pharmaceutical Inc.

AstraZeneca PLC

Daiichi Sankyo Co., Ltd.

Novo Nordisk A/S

Additional Topics

Gene Therapy Launches Commercial Immune Disorders BioPharmaceutical

More from Gene Therapies

More from Advanced Therapies

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window